According to 42.8% of respondents (3/7), the administration of nirmatrelvir + ritonavir led to hypertriglyceridemia, nausea and vomiting, increased CPK levels, increased levels of concomitant sirolimus, and headache, respectively. The gene discussed is PIK3C2A; the disease is hypertriglyceridemia.